Executive summary. Diversion prevention is the work of keeping 340B drugs to the circumstances the program and the covered entity’s policy allow.
Definition
340B diversion is the use of a 340B drug in a way that does not meet program requirements.
Where this work lives in Attergo
Compliance and inventory teams use Attergo Compliance Tracing, policies, tasks, and inventory records to organize the work around a 340B review. Keep the records aligned to your organization’s approved policy, and bring in the program lead whenever an item needs judgment.
A sound process checks the patient, the care setting, the prescriber relationship, the location, and anything else your policy and program guidance require. Missing information should send the transaction to review.
Review and follow up
Train staff on when to stop and ask. Retain the policy version, the relevant records, and the final decision, so the organization can explain its reasoning if the transaction is reviewed later.
Final decisions stay with the role your organization holds accountable for them. Record the decision on the item, with the evidence behind it, so the next person to open it does not start over.
Frequently asked questions
Who should use this Attergo workspace?
The role that owns the next action leads it: a billing specialist, an authorization coordinator, an inventory lead, a pharmacist, a compliance lead, or a finance reviewer. Access follows the role your organization assigns.
Referenced standards and further reading
- HRSA: 340B program integrity ↗Health Resources and Services Administration
Related articles
340B eligibility depends on dispense context →